financetom
Business
financetom
/
Business
/
Goldman Sachs' Trading Activity Powers Q4 Outperformance, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman Sachs' Trading Activity Powers Q4 Outperformance, Oppenheimer Says
Jan 16, 2025 10:08 AM

12:34 PM EST, 01/16/2025 (MT Newswires) -- Goldman Sachs' ( GS ) Q4 results demonstrate the bank's operational leverage and efficiency gains as it showed the ability to exceed revenue expectations without proportional increases in expenses, Oppenheimer said in a note on Thursday.

The lender's Q4 earnings of $11.95 per share exceeded consensus estimates of $8.21 driven by trading revenues, which contributed $1.8 billion more than projected to total revenue of $13.9 billion, Oppenheimer analysts said.

Equity underwriting was responsible for a 24% growth in investment banking revenue while merger and acquisition activity declined in line with broader industry trends, according to the note.

The firm expects deal activity to rebound by 2025-2026 and Goldman Sachs ( GS ) is well-positioned to capitalize on the anticipated recovery with an "enormous pent-up demand as M&A volumes in 2024 were the lowest since 2014."

The brokerage raised its price target to $687 from $639 while reiterating an outperform rating on the stock.

Shares were 1.1% higher in recent trading.

Price: 612.50, Change: +6.58, Percent Change: +1.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canadian telecom firm Telus's Q2 revenue up 2%, sells stake in tower firm for C$1.26 bln
Canadian telecom firm Telus's Q2 revenue up 2%, sells stake in tower firm for C$1.26 bln
Aug 1, 2025
Overview * Telus Q2 2025 operating revenue rises 2% yr/yr to C$5.1 bln * Adjusted EBITDA grows 1%, reflecting cost reduction and subscriber growth * Co sells 49.9% stake in newly formed wireless tower infrastructure operator Terrion for C$1.26 bln to reduce leverage Outlook * Telus ( TU ) reaffirms 2025 revenue growth target of 2-4% for TTech * Company...
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Aug 1, 2025
Aug 1 (Reuters) - Moderna ( MRNA ) topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts. The company also lowered its 2025 sales forecast to $1.5 billion to $2.2 billion, cutting $300 million from the top end, as UK revenue deliveries shifted into early...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
BRIEF-Arrowhead Subsidiary Visirna Sells Rights To Hypertriglyceridemia Candidate Plozasiran In Greater China To Sanofi
BRIEF-Arrowhead Subsidiary Visirna Sells Rights To Hypertriglyceridemia Candidate Plozasiran In Greater China To Sanofi
Aug 1, 2025
Aug 1 (Reuters) - Arrowhead Pharmaceuticals Inc ( ARWR ) : * ARROWHEAD SUBSIDIARY VISIRNA SELLS RIGHTS TO HYPERTRIGLYCERIDEMIA CANDIDATE PLOZASIRAN IN GREATER CHINA TO SANOFI * ARROWHEAD PHARMACEUTICALS INC ( ARWR ) - SANOFI TO PAY $130 MILLION UPFRONT, $265 MILLION IN MILESTONES * ARROWHEAD PHARMACEUTICALS INC ( ARWR ) - SANOFI RECEIVES EXCLUSIVE LICENSE FOR PLOZASIRAN IN CHINA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved